The Food and Drug Administration (FDA) has suspended the blood bank licence of Jaslok hospital at Peddar Road for 15 days.
The FDA move follows the death of a leukaemia patient, Deepti Makhijani, 21, last December. Makhijani's family alleged that she died after the hospital staff gave her a transfusion of B-positive blood instead of A-positive blood on December 8.
Doctors at the hospital maintained that Makhijani died due to complete organ failure. The Gamdevi police filed a first information report (FIR) against the hospital on December 14.
“Following the complaint with the police, we inspected the blood bank and sent them a show-cause notice. We gave the hospital a chance to give their version and waited for their reply. We also spoke to Makhijani’s parents. Last week, we sent the hospital a notice of suspension of licence for 15 days by post,” said PR Uttarwar, joint commissioner, FDA.
However, hospital officials said on Wednesday that they had not received a copy of the suspension notice and the blood bank was still functioning.
“We conducted an inquiry in the hospital, but no one is under suspicion. The administration of the wrong blood group is an error on part of the nurses. We have counselled them,” said Dr AH Ganguly, medical superintendent of the hospital.
However, the FDA clarified that the patient did not die due to the wrong administration of blood.
“We have suspended their licence because there was an error on their part. But there is no question of the patient dying because of the error as the blood was transfused only for four to five minutes,” said Uttarwar.
With the blood bank not functioning, the hospital may have to cancel planned surgeries.
“I am not concerned with suspension of the blood bank licence at all. I am more concerned with the doctor who treated Deepti being punished. The doctor signs the prescription before the blood is transfused in the patient’s body. They should be held accountable,” said Makhijani’s father, Narendra.